To explore the relationship between the expression of synbindin in peripheral blood monocytes and disease activity in patients with inflammatory bowel disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100049140

Enrollment

Unknown

Registered

2021-07-23

Start date

2021-07-26

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Disease

Interventions

Healthy control group:No

Patients with inflammatory bowel disease:No

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. IBD patients hospitalized in Dongfang Hospital Affiliated to Tongji University and Renji Hospital from July 26, 2021 to October 21, 2021, including active stage and remission stage, including patients admitted due to disease attack and admitted to hospital for evaluation; 2. Patients with a clear diagnosis of IBD based on clinical, endoscopic and pathological findings.

Exclusion criteria

Exclusion criteria: 1. The diagnosis of IBD is not clear; 2. Under the age of 18; 3. Suffering from other autoimmune diseases at the same time.

Design outcomes

Primary

Measure	Time frame
synbindin;	—

Countries

China

Contacts

Public ContactYan Xiaohan

Shanghai East Hospital, School of Medicine, Tongji University

yanxiaohan8@126.com+86 13621783915

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026